Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Roche Holding AG (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RHHBY
Over the counter
2834
https://www.roche.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Roche Holding AG (ADR)
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
- May 2nd, 2024 3:13 pm
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
- May 2nd, 2024 1:42 pm
Q1 2024 Sarepta Therapeutics Inc Earnings Call
- May 2nd, 2024 10:01 am
The top pharmaceutical companies by R&D expenditure
- May 2nd, 2024 7:01 am
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
- May 1st, 2024 10:42 am
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
- Apr 30th, 2024 6:00 am
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
- Apr 24th, 2024 1:11 pm
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
- Apr 24th, 2024 5:34 am
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- Apr 24th, 2024 5:00 am
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
- Apr 19th, 2024 2:11 pm
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
- Apr 19th, 2024 1:15 pm
Roche wins FDA OK for Alecensa in early lung cancer
- Apr 19th, 2024 10:38 am
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Apr 19th, 2024 5:00 am
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
- Apr 18th, 2024 8:35 pm
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
- Apr 17th, 2024 6:06 am
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- Apr 17th, 2024 6:00 am
Adaptimmune (ADAP) Down on End of Collaboration With Roche
- Apr 15th, 2024 6:12 pm
Roche reports survival data for new dual-acting lymphoma drug
- Apr 15th, 2024 11:57 am
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
- Apr 15th, 2024 11:31 am
Roche to distribute Prenosis’ AI sepsis detection tool in US
- Apr 15th, 2024 10:21 am
Scroll